← Eichor
Condition: Secondary Myelofibrosis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Secondary Myelofibrosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplas
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07228624The Patient Cohort of the National Center for Precision Medicine in Leukemia
Phase N/A · 3 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05326919Research Platform Myelofibrosis and Anemia
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06976918Therapeutic RSK1 Targeting in Myelofibrosis
Phase 1 · 1 location(s) · Washington University School of Medicine · NCT07379125SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT011378253'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Phase 2 · 33 location(s) · GlaxoSmithKline · NCT06517875Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Ste
EARLY_Phase 1 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06398457AlloHCT With PegINFa for Myelofibrosis
Phase 1 · 1 location(s) · University of Utah · NCT05535764Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Ne
Phase 2 · 1 location(s) · University of Washington · NCT04282187Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04370301A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Phase 1/Phase 2 · 84 location(s) · Sumitomo Pharma America, Inc. · NCT04176198Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137643A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
Phase 1 · 3 location(s) · Aspera Biomedicines, Inc. · NCT07250646Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera
Phase N/A · 26 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06516406RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis
Phase 2 · 18 location(s) · Ryvu Therapeutics SA · NCT06397313
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.